Back to Agenda
The Laboratory-Developed Tests Final Rule: New Developments and Compliance Insights
Session Chair(s)
Courtney Granville, PhD, MPH
Chief Scientific Officer
GO2 For Lung Cancer, United States
The FDA has published a final rule to regulate laboratory-developed tests (LDT) as medical devices under the Federal Food, Drug, and Cosmetic Act. The publication of the rule has far-reaching implications for the quality and availability of diagnostic tests in the United States, as well as impacts on pharmaceutical product research. This session will discuss the final rule in a panel format, focusing on the impact to various stakeholders, as well as current compliance efforts and next steps for ensuring compliance. The session will also address the impact of the recent election, legislative and executive actions, and litigation, on the FDA’s regulation of laboratory developed tests.
Learning Objective : List requirements of the LDT Final Rule and phased approach to regulation; Summarize implications of the FDA LDT Final Rule for patients, developers, health care systems, providers and regulatory decision making; Discuss approaches to implementing requirements of the final rule.
Speaker(s)
Panelist
Megan Doyle, JD, MPH
Eli Lilly & Company, United States
Associate Vice President, Assistant General Counsel - Diagnostics
Panelist
Lia Ridout
N/A, United States
Patient Advocate
Panelist
Carly McWilliams, MBA
Roche Diagnostics, United States
Head of Regulatory Policy
Panelist
Nathan Brown, JD
Akin Gump Strauss Hauer & Feld LLP, United States
Partner
Have an account?